These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis. Ingram DK; Spangler EL; Iijima S; Ikari H; Kuo H; Greig NH; London ED Life Sci; 1994; 55(25-26):2037-49. PubMed ID: 7997063 [TBL] [Abstract][Full Text] [Related]
8. The presence of the APP(swe) mutation in mice does not increase the vulnerability of cholinergic basal forebrain neurons to neuroinflammation. Wenk GL; McGann-Gramling K; Hauss-Wegrzyniak B Neuroscience; 2004; 125(3):769-76. PubMed ID: 15099690 [TBL] [Abstract][Full Text] [Related]
9. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Lipton SA Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105 [TBL] [Abstract][Full Text] [Related]
10. The cholinergic system in aging and neuronal degeneration. Schliebs R; Arendt T Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918 [TBL] [Abstract][Full Text] [Related]
11. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665 [TBL] [Abstract][Full Text] [Related]
12. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease. Chen G; Chen P; Tan H; Ma D; Dou F; Feng J; Yan Z Neurobiol Aging; 2008 Dec; 29(12):1795-804. PubMed ID: 17555845 [TBL] [Abstract][Full Text] [Related]
13. The glutamatergic system and Alzheimer's disease: therapeutic implications. Butterfield DA; Pocernich CB CNS Drugs; 2003; 17(9):641-52. PubMed ID: 12828500 [TBL] [Abstract][Full Text] [Related]
14. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Grossberg GT; Edwards KR; Zhao Q J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811 [TBL] [Abstract][Full Text] [Related]
15. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. Schliebs R; Arendt T J Neural Transm (Vienna); 2006 Nov; 113(11):1625-44. PubMed ID: 17039298 [TBL] [Abstract][Full Text] [Related]
16. Altered synaptic function in Alzheimer's disease. Bell KF; Claudio Cuello A Eur J Pharmacol; 2006 Sep; 545(1):11-21. PubMed ID: 16887118 [TBL] [Abstract][Full Text] [Related]
17. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Parsons CG; Stöffler A; Danysz W Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591 [TBL] [Abstract][Full Text] [Related]
18. What is the rationale for new treatment strategies in Alzheimer's disease? Rogawski MA CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294 [TBL] [Abstract][Full Text] [Related]